The report provides comprehensive information on the
therapeutics under development for Diabetic Macular Edema, complete with
analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Diabetic Macular Edema and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619281-diabetic-macular-edema-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players
in the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Diabetic Macular Edema
- The report reviews pipeline therapeutics for Diabetic
Macular Edema by companies and universities/research institutes based on information
derived from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Macular
Edema therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Macular Edema therapeutics
based on drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Diabetic Macular Edema
Reasons to
buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Diabetic Macular Edema
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Diabetic Macular Edema pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Macular Edema - Overview 10
Pipeline Products for Diabetic Macular Edema - Comparative
Analysis 11
Diabetic Macular Edema - Therapeutics under Development by
Companies 12
Diabetic Macular Edema - Therapeutics under Investigation by
Universities/Institutes 16
Diabetic Macular Edema - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Macular Edema - Products under Development by
Companies 21
Diabetic Macular Edema - Products under Investigation by
Universities/Institutes 24
Diabetic Macular Edema - Companies Involved in Therapeutics
Development 25
Aciont Inc. 25
ActiveSite Pharmaceuticals, Inc. 26
Adverum Biotechnologies, Inc. 27
Aerpio Therapeutics, Inc. 28
Allergan Plc 29
Ampio Pharmaceuticals, Inc. 30
Araim Pharmaceuticals, Inc. 31
Astellas Pharma Inc. 32
Access Report @ https://www.wiseguyreports.com/reports/619281-diabetic-macular-edema-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment